Clinical development of an anti-GPC-1 antibody for the treatment of cancer

Introduction Glypican-1 (GPC-1) is a heparan sulfate proteoglycan (HSPG) overexpressed in multiple cancers. Multiple studies indicate the prominence of this cancer biomarker with significant diagnostic and therapeutic potential. Recent advances in monoclonal antibody (mAb)-based biopharmaceuticals targeting GPC-1 show promise toward managing GPC-1-positive solid tumors clinically. Areas covered This review addresses GPC-1 targeting antibodies for cancer therapy, in preclinical and clinical development. Current and emerging development of different anti-GPC-1 antibody formats based on mechanism of action and application are also discussed. Expert opinion Clinical development of novel anti-GPC-1 antibody-based formats is still in its early days. Using the patented anti-GPC-1 Miltuximab (R) as a case study, we have made an attempt to illustrate a pathway for preclinical to clinical translation, which could be useful for newer GPC-1 targeting immunotherapy agents.

Automated summary

This article reviews the application and development of antibodies targeting glypican-1 (GPC-1) in cancer therapy. The current and emerging development of different antibody formats based on mechanism of action and application are discussed.